Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024 - ResearchAndMarkets.com

DUBLIN--()--The "Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.

The global hospital acquired disease testing market was worth US$ 876 Million in 2018. Hospital acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and the emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Another reason can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patients' own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

The market for hospital acquired disease testing is currently exhibiting double digit growth rates. Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market. Looking forward, the market value is projected to reach US$ 2,190 Million by 2024, exhibiting a CAGR of around 16.5% during 2019-2024.

Market Summary:

Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.

Key Topics Covered:

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Hospital Acquired Disease Testing Market

5.1 Market Overview

5.2 Market Performance

5.3 Market Breakup by Indication

5.4 Market Breakup by Region

5.5 Market Forecast

5.6 SWOT Analysis

5.6.1 Overview

5.6.2 Strengths

5.6.3 Weaknesses

5.6.4 Opportunities

5.6.5 Threats

5.7 Value Chain Analysis

5.8 Porters Five Forces Analysis

5.8.1 Overview

5.8.2 Bargaining Power of Buyers

5.8.3 Bargaining Power of Suppliers

5.8.4 Degree of Competition

5.8.5 Threat of New Entrants

5.8.6 Threat of Substitutes

5.9 Price Analysis

6 Market Breakup by Indication

6.1 UTI (Urinary Tract Infection)

6.1.1 Market Trends

6.1.2 Market Forecast

6.2 SSI (Surgical Site Infection)

6.2.1 Market Trends

6.2.2 Market Forecast

6.3 Pneumonia

6.3.1 Market Trends

6.3.2 Market Forecast

6.4 Bloodstream Infections

6.4.1 Market Trends

6.4.2 Market Forecast

6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)

6.5.1 Market Trends

6.5.2 Market Forecast

6.6 Others

6.6.1 Market Trends

6.6.2 Market Forecast

7 Market Breakup by Region

7.1 North America

7.1.1 Market Trends

7.1.2 Market Forecast

7.2 Europe

7.2.1 Market Trends

7.2.2 Market Forecast

7.3 Asia Pacific

7.3.1 Market Trends

7.3.2 Market Forecast

7.4 Middle East and Africa

7.4.1 Market Trends

7.4.2 Market Forecast

7.5 Latin America

7.5.1 Market Trends

7.5.2 Market Forecast

8 Competitive Landscape

8.1 Market Structure

8.2 Key Players

8.3 Profiles of Key Players

8.3.1 Abbott Laboratories

8.3.2 Alere, Inc.

8.3.3 Becton, Dickinson and Company

8.3.4 bioMerieux SA

8.3.5 F. Hoffmann-La Roche Ltd.

8.3.6 Hologic, Inc.

8.3.7 QIAGEN

8.3.8 Siemens Healthcare

8.3.9 Diatherix Laboratories, Inc.

8.3.10 Meridian Bioscience, Inc.

8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)

8.3.12 Cepheid, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/swt6x1

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Disease Testing

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Disease Testing